Focus on Lipids Care

Back to articles

Bile acid sequestrant: Useful adjuncts to statins

May 1, 2006
  • Advising on this article:
  • Amber Briggs

KEY POINT

A study recently reported in American Journal of Cardiology is the first trial to establish that adding colesevelam (WelChol—Daiichi Sankyo, Inc.) to stable statin therapy further reduces mean LDL cholesterollevels and significantly reduces high-sensitivity C-reactive protein (hs-CRP) levels.

SOURCES

Bays HE et al. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006;97:1198–205.

Miller DT et al. Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet. 2005;69:623–38.

Zee RY et al. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis. 2002;162:217–9.

Recent Articles

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.